Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA s MAT2A inhibitor, in combination with sacituzumab-govitecan-hziy Gilead s Trop-2 directed ADC,.
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2023 /PRNewswire/ IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics,.
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 /PRNewswire/ IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics,.
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 /PRNewswire/ IDEAYA Biosciences, Inc. today announced the closing of its underwritten public offering of 5,797,872 shares of its common stock at a.